Stroke prevention for non-valvular atrial fibrillation: How to make the right choice of directly acting oral anticoagulants?
Крюков Н. Н., Сайутина Е. В., Осадчук А. М., Осадчук М. А.
Российский кардиологический журнал
Т. 24, Вып. 1, С. 94-102
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.15829/1560-4071-2019-1-94-102
Аннотация:
Patients with atrial fibrillation have a high risk of developing stroke and death, which requires constant anticoagulant support. In this regard, the physician faces the difficult task of selecting the appropriate oral anticoagulant for patient with individual risk factors and comorbidities. Currently, three non-vitamin K antagonist oral anticoagulants or directly acting oral anticoagulants have been registered in the Russia, which in large randomized clinical trials (RCTs) were compared with warfarin in the prevention of stroke and systemic embolism. The present article analyzes the data of RCTs, postmarketing studies of oral anticoagulants, and presents groups of patients for whom these drugs are preferred. The choice of oral anticoagulants for the prevention of stroke in the following subgroups of patients with atrial fibrillation is discussed: patients with one stroke risk factor (CHA2DS2VASc1 in men or 2 in women), patients of different age groups, patients with concomitant corona
Ключевые слова:
Anticoagulation; Non-valvular atrial fibrillation; Nonvitamin k antagonist oral anticoagulants; Stroke prevention
anticoagulant agent; antivitamin K; warfarin; acute coronary syndrome; anticoagulant therapy; Article; atrial fibrillation; cerebrovascular accident; CHA2DS2-VASc score; chronic kidney failure; comorbidity; coronary artery disease; drug choice; drug efficacy; drug safety; embolism; gastrointestinal hemorrhage; heart failure; human; hypertension; randomized controlled trial (topic); risk factor; Russian Federation
Язык текста: Русский
ISSN: 2618-7620
Крюков Н. Н.
Сайутина Е. В.
Осадчук А. М.
Осадчук М. А. Михаил Алексеевич 1951-
Kryukov N. N.
Sayutina E. V.
Osadchuk A. M.
Osadchuk M. A. Mikhail Alekseevich 1951-
Stroke prevention for non-valvular atrial fibrillation: How to make the right choice of directly acting oral anticoagulants?
Текст визуальный непосредственный
Российский кардиологический журнал
ООО "Силицея-Полиграф"
Т. 24, Вып. 1 С. 94-102
2019
Статья
Anticoagulation Non-valvular atrial fibrillation Nonvitamin k antagonist oral anticoagulants Stroke prevention
anticoagulant agent antivitamin K warfarin acute coronary syndrome anticoagulant therapy Article atrial fibrillation cerebrovascular accident CHA2DS2-VASc score chronic kidney failure comorbidity coronary artery disease drug choice drug efficacy drug safety embolism gastrointestinal hemorrhage heart failure human hypertension randomized controlled trial (topic) risk factor Russian Federation
Patients with atrial fibrillation have a high risk of developing stroke and death, which requires constant anticoagulant support. In this regard, the physician faces the difficult task of selecting the appropriate oral anticoagulant for patient with individual risk factors and comorbidities. Currently, three non-vitamin K antagonist oral anticoagulants or directly acting oral anticoagulants have been registered in the Russia, which in large randomized clinical trials (RCTs) were compared with warfarin in the prevention of stroke and systemic embolism. The present article analyzes the data of RCTs, postmarketing studies of oral anticoagulants, and presents groups of patients for whom these drugs are preferred. The choice of oral anticoagulants for the prevention of stroke in the following subgroups of patients with atrial fibrillation is discussed: patients with one stroke risk factor (CHA2DS2VASc1 in men or 2 in women), patients of different age groups, patients with concomitant corona